Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Odi Bruckman

04:56 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Odi Bruckman" found in our extensive news archives from over 250 global news sources.

More Information about Odi Bruckman on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odi Bruckman for you to read. Along with our medical data and news we also list Odi Bruckman Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odi Bruckman Companies for you to search.

Showing News Articles 1–25 of 3,500+ from Odi Bruckman

Saturday 9th March 2019

At #ECCO2019 we’re excited to present late-breaking data from the first ever head-to-head study comparing the efficacy of two biologic therapies in #ulcerativecolitis. #ECCO19 #TakedaGI http://ow.ly/oeFN30nYRtG pic.twitter.com/aEdpjJxTKk

At #ECCO2019 we’re excited to present late-breaking data from the first ever head-to-head study comparing the efficacy of two biologic therapies in #ulcerativecolitis. #ECCO19 #TakedaGI http://ow.ly/oeFN30nYRtG  pic.twitter.com/aEdpjJxTKk

Friday 8th March 2019

Biotech updates 03/08: $AMAG confirmatory trial fail -18% $ALT offering -37% $SNY $REGN nasal polyps PDUFA June 26 $PULM +39% $BPTH -46% Pipeline updates $ALDX $ALLO $CHMA $CNAT $ELOX $LPTX $MRSN $ONCY $RYTM $TGTX https://www.biopharmcatalyst.com/news/20

Biotech updates 03/08: $AMAG confirmatory trial fail -18% $ALT offering -37% $SNY $REGN nasal polyps PDUFA June 26 $PULM +39%

$tril announces closing of $15m public offering.pic.twitter.com/Q8sWVfxKEf

$tril announces closing of $15m public offering. pic.twitter.com/Q8sWVfxKEf

Medtronic board approves $6 billion more in stock buybacks https://on.mktw.net/2EIdV8i 

Medtronic board approves $6 billion more in stock buybacks https://on.mktw.net/2EIdV8i 

$SELB CFO resigns effective March 31

$SELB CFO resigns effective March 31

$CHMA Top line data from Ph3 CHIASMA OPTIMAL trial expected in Q3 2019. Ended 2018 with $41M cash https://finance.yahoo.com/news/chiasma-reports-fourth-quarter-end-210500112.html …

$CHMA Top line data from Ph3 CHIASMA OPTIMAL trial expected in Q3 2019. Ended 2018 with $41M cash https://finance.yahoo.com/news/chiasma-reports-fourth-quarter-end-210500112.html …

A combo that includes Immunotherapy is now approved for a type of breast cancer for the first time. Another important first. https://www.reuters.com/article/us-roche-immunotherapy/roches-tecentriq-wins-us-approval-for-aggressive-breast-cancer-idUSKCN1QP20

A combo that includes Immunotherapy is now approved for a type of breast cancer for the first time. Another important first. https://www.reuters.com/article/us-roche-immunotherapy/roches-tecentriq-wins-us-approval-for-aggressive-breast-cancer-idUSKCN1QP20C …

$ALXN Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve https://www.businesswire.com/news

$ALXN Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve https://www.businesswire.com/news/home/20190308005101/en/Alexion-Announces-Publication-Interim-Data-Phase-3 …

$SBOT to own 10% of new company, merger with Edesa Biotech

$SBOT to own 10% of new company, merger with Edesa Biotech

#Breaking SpaceX’s Dragon capsule has splashed down in the Atlantic Ocean off the coast of Florida after departing from the International Space Station

#Breaking SpaceX’s Dragon capsule has splashed down in the Atlantic Ocean off the coast of Florida after departing from the International Space Station

Very odd. The biggest one month plunge in the underemployment rate in historypic.twitter.com/olTIrnnkkV

Very odd. The biggest one month plunge in the underemployment rate in history pic.twitter.com/olTIrnnkkV

$ARNA Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation https://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-phase-2-data-for-etrasimod-and-olorinab-at-the-14th-

$ARNA Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation https://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-phase-2-data-for-etrasimod-and-olorinab-at-the-14th-congress-of-european-crohns-and-colitis-organisation-300808996.html …

Learn about the basics of FDA’s drug regulatory process and the science that supports CDER’s mission in this free online CE course from FDA! http://fdadrugregulations.e-paga.com/ pic.twitter.com/6RgL6q17bF

Learn about the basics of FDA’s drug regulatory process and the science that supports CDER’s mission in this free online CE course from FDA! http://fdadrugregulations.e-paga.com/  pic.twitter.com/6RgL6q17bF

BREAKING: U.S. economy added only 20K jobs in February vs. expectation of 180K increase; unemployment rate at 3.8% http://cnbc.com/id/105782409 pic.twitter.com/DXEJileBWK

BREAKING: U.S. economy added only 20K jobs in February vs. expectation of 180K increase; unemployment rate at 3.8% http://cnbc.com/id/105782409  pic.twitter.com/DXEJileBWK

9 out of 10 times I’d argue the #employment data are not particularly useful in telling us where #economy is going because the figures are lagging. However today may be the exception because a strong #NFP would corroborate the US vs Rest of World decou

9 out of 10 times I’d argue the #employment data are not particularly useful in telling us where #economy is going because the figures are lagging. However today may be the exception because a strong #NFP would corroborate the US vs Rest of World decoupling view.

$AMAG Topline Results From the PROLONG Trial Evaluating Makena®, did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints https://globenewswire.com/news-release/2019/03/08/1750567/0/e

$AMAG Topline Results From the PROLONG Trial Evaluating Makena®, did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints https://globenewswire.com/news-release/2019/03/08/1750567/0/en/AMAG-Pharmaceuticals-Announces-Topline-Results-From-the-PROLONG-Trial-Evaluating-Makena-hydroxyprogesterone-caproate-injection.html&nb...

$SYRS initiated with an Outperform at JMP $18

$SYRS initiated with an Outperform at JMP $18

$TGTX Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials https://globenewswire.com/news-release/2019/03/08/1750544/0/en/TG-Therapeutics-Announces-Positive-Data-Safety-Monitoring-Board-Reviews-of-UNITY-CLL-an

$TGTX Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials https://globenewswire.com/news-release/2019/03/08/1750544/0/en/TG-Therapeutics-Announces-Positive-Data-Safety-Monitoring-Board-Reviews-of-UNITY-CLL-and-UNITY-NHL-Clinical-Trials.html …

$ELOX 4Q 2018. Top line data from Phase 2 clinical trial for ELX-02 in cystic fibrosis in the U.S. and Europe in 2019 https://finance.yahoo.com/news/eloxx-pharmaceuticals-reports-fourth-quarter-120000612.html …

$ELOX 4Q 2018. Top line data from Phase 2 clinical trial for ELX-02 in cystic fibrosis in the U.S. and Europe in 2019 https://finance.yahoo.com/news/eloxx-pharmaceuticals-reports-fourth-quarter-120000612.html …

$ALDX Results from ALLEVIATE Phase 3 Clinical Allergic Conjunctivitis Expected in Early 2019 RENEW Adaptive Phase 3 Trial in Dry Eye Disease Expected to Begin in First Half of 2019 - Results SOLACE Phase 3 Noninfectious Anterior Uveitis Second Half 2019

$ALDX Results from ALLEVIATE Phase 3 Clinical Allergic Conjunctivitis Expected in Early 2019 RENEW Adaptive Phase 3 Trial in Dry Eye Disease Expected to Begin in First Half of 2019 - Results SOLACE Phase 3 Noninfectious Anterior Uveitis Second Half 2019 http://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-year-end-2018-financial-results …

$SEEL registered for sale up to 15.9M shares by stockholders http://archive.fast-edgar.com//20190308/A3U2822CY222I2C2222N2CZ2CNS8822232B2/ …

$SEEL registered for sale up to 15.9M shares by stockholders http://archive.fast-edgar.com//20190308/A3U2822CY222I2C2222N2CZ2CNS8822232B2/ …

$ACOR Andrew Hindman CBO leaving

$ACOR Andrew Hindman CBO leaving

$TLRY initiated with an Underperform at Jefferies. $61

$TLRY initiated with an Underperform at Jefferies. $61

Sweden has the most generous paid parental leave policy in the world https://nyti.ms/2TCuYC6 

Sweden has the most generous paid parental leave policy in the world https://nyti.ms/2TCuYC6 

$MRSN Company Plans to Report XMT-1536 Dose Escalation Data in Q2 2019. Ended 2018 with $70M in Cash

$MRSN Company Plans to Report XMT-1536 Dose Escalation Data in Q2 2019. Ended 2018 with $70M in Cash


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks